NASDAQ : CTOR
Citius Oncology, Inc. — Key statistics
Healthcare · Drug Manufacturers - Specialty & Generic · United States
Last price 0.5295 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 56.00M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 58.59M |
| Enterprise Value | 52.24M |
Dates
| Measure | Value |
|---|
| Earnings Date | Dec 22, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 105.76M |
| Shares Outstanding | 105.76M |
| Shares Change (YoY) | +31.40% |
| Shares Change (QoQ) | +7.86% |
| Owned by Insiders (%) | 0.02% |
| Owned by Institutions (%) | 5.20% |
| Float | 30.98M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 8.25 |
| Forward PS | 0.84 |
| PB Ratio | 1.45 |
| P/TBV Ratio | 1.45 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 7.35 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 0.73 |
| Quick Ratio | 0.29 |
| Debt / Equity | 0.25 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -129.05 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -126.58% |
| Return on Assets (ROA) | -29.12% |
| Return on Invested Capital (ROIC) | -68.37% |
| Return on Capital Employed (ROCE) | -89.06% |
| Weighted Average Cost of Capital (WACC) | 20.78% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.07 |
| Inventory Turnover | 0.09 |
Taxes
| Measure | Value |
|---|
| Income Tax | 189,923 |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 3.57 |
| 52-Week Price Change | -68.34% |
| 50-Day Moving Average | 0.84 |
| 200-Day Moving Average | 0.84 |
| Relative Strength Index (RSI) | 29.71 |
| Average Volume (20 Days) | 125,834 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 227,455 |
| Short Previous Month | 289,717 |
| Short % of Shares Out | 0.22% |
| Short % of Float | 0.73% |
| Short Ratio (days to cover) | 2.09 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 7.11M |
| Gross Profit | 5.32M |
| Operating Income | -47.47M |
| Pretax Income | -45.87M |
| Net Income | -46.06M |
| EBITDA | n/a |
| EBIT | -47.47M |
| Loss Per Share | -$0.49 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 16.56M |
| Total Debt | 10.21M |
| Net Cash | 6.35M |
| Net Cash Per Share | $0.06 |
| Equity (Book Value) | 40.38M |
| Book Value Per Share | 0.38 |
| Working Capital | -16.08M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -19.39M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | n/a |
| Net Borrowing | 9.64M |
| Free Cash Flow | -19.39M |
| FCF Per Share | -$0.18 |
Margins
| Measure | Value |
|---|
| Gross Margin | 74.82% |
| Operating Margin | -668.15% |
| Pretax Margin | -645.64% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -31.40% |
| Shareholder Yield | n/a |
| Earnings Yield | -89.01% |
| FCF Yield | -33.09% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | -1.88 |
| Piotroski F-Score | 2 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |